|本期目录/Table of Contents|

[1]韩丽娟.罗氟司特治疗慢性阻塞性肺疾病研究进展[J].慢性病学杂志,2020,21(05):687-689.
点击复制

罗氟司特治疗慢性阻塞性肺疾病研究进展

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
21
期数:
2020年05期
页码:
687-689
栏目:
综 述
出版日期:
2020-05-28

文章信息/Info

Title:
-
作者:
韩丽娟
内蒙古医科大学，呼和浩特 010010
Author(s):
-
关键词:
慢性阻塞性肺疾病; 治疗; 罗氟司特
Keywords:
-
分类号:
R569
DOI:
-
摘要:
慢性阻塞性肺疾病（简称慢阻肺）是一种常见的慢性呼吸系统疾病。由于慢阻肺较高的发病率和致死率， 在现阶段寻找更优的治疗和早期干预手段一直是呼吸界刻不容缓的任务。本文对罗氟司特治疗慢性阻塞性肺疾病 的研究进展进行综述。
Abstract:
-

参考文献/References:

[1] Cox M, O’connor C, Bigg K, etal. The feasibility of ear-ly pulmonary rehabilitation and activity after COPD exacer-bations: external pilot randomised controlled trial, qualita-tive case study and exploratory economic evaluation [J]. Health Technol Assess,2018,22(11):1-204. [2] Martinez FJ, Rabe KF, Ferguson GT,et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in pa-tients with COPD [J]. Chest, 2017,151(2):340-357. [3] Rodrigo GJ, Castro-rodriguez JA, Plaza V. Safety and ef-ficacy of combined long- acting beta- agonists and inhaled corticosteroids vs long- acting beta- agonists monotherapy for stable COPD: a systematic review [J]. Chest, 2009,136 (4):1029-1038. [4] Matera MG, Calzetta L, Puxeddu E,et al. A safety com-parison of LABA + LAMA vs LABA + ICS combination therapy for COPD [J]. Expert Opin Drug Saf, 2018,17(5): 509-517. [5] 李东伟.支气管哮喘临床诊治展[J].海峡药学,2016,28(5):155-157. [6] 王瑞倩,卞涛.选择性磷酸二酯酶抑制剂罗氟司特在慢性阻塞性 肺疾病抗炎作用的研究进展[J].中华哮喘杂志(电子版),2012,6 (6):441-446. [7] MilaraJ, Armengot M. Roflumilast N-oxide, a PDE4 in-hibitor, improves cilia motility and ciliated human bronchi-al epithelial cells compromised by cigarette smoke in vitro [J]. Br J Pharmacol, 2012,166(8):2243-2262. [8] O’Donnell DE. Breathlessness in patients with chronic air-flow limitation: mechanisms and management [J]. Chest, 1994,106(3):904-912. [9] 郑劲平.磷酸二酯酶4抑制剂治疗慢性阻塞性肺疾病的个性化选 择[J].中国实用内科杂志,2015,35(5):386-388. [10] Rabe KF, Bateman ED, O’Donnell D,et al. Roflumilast-an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial [J]. Lan-cet, 2005,366(948):563-571. [11] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺 疾病诊治指南（2013年修订版）[J].中国医学前言杂志(电子版), 2014,6(2):67-90. [12] 邢贞建,江慧贤,程武,等.新型磷酸二酯酶4抑制剂罗氟普兰对炎 性因子的影响[J].今日药学,2019,29(9):401-402,409. [13] Hanania NA, Calverley PMA, Dransfield MT, et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD [J]. Respir Med,2014,108(2):366-375. [14] 夏增辉,张毅伟,陈莹,等.罗氟司特对CUMS小鼠抑郁行为的影 响[J].神经药理学报,2019,9(4):40. [15] Joo H, Han D, Lee JH, et al. Incidence of adverse ef-fects and discontinuation rate between patients receiving 250 micrograms and 500 micrograms of Roflumilast: a comparative study [J]. Tuberc Respir Dis (Seoul), 2018,81 (4):299-304. [16] 程莎,代泽兰,肖创,等.罗氟司特对亚洲慢性阻塞性肺疾病患者 肺功能影响的Meta分析[J].中国药房,2019,30(8):1112-1117. [17] Lee JS, Hong YK, Park TS,et al. Efficacy and safety of roflumilast in Korean patients with COPD [J]. Yonsei Med J, 2016,57(4):928-935. [18] Liu DY, Wang ZG, Gao Y,etal. Effect and safety of ro-flumilast for chronic obstructive pulmonary disease in Chi-nese patients [J]. Med,2018,97(7):e9864.

备注/Memo

备注/Memo:
作者简介：韩丽娟，硕士，研究方向：呼吸系统疾病 通信作者：韩丽娟，E-mail：chenweihua43724@163.com
更新日期/Last Update: 2020-05-28